Trade

with

MannKind Corp
(NASDAQ: MNKD)
AdChoices
5.65
+0.26
+4.82%
After Hours :
5.66
+0.01
+0.18%

Open

5.42

Previous Close

5.39

Volume (Avg)

4.29M (8.10M)

Day's Range

5.33-5.65

52Wk Range

3.80-11.48

Market Cap.

2.27B

Dividend Rate ( Yield )

-

Beta

1.37

Shares Outstanding

402.38M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 0

    • Net Income

    • -191.49M

    • Market Cap.

    • 2.27B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.37

    • Forward P/E

    • -555.56

    • Price/Sales

    • -

    • Price/Book Value

    • -49.02

    • Price/Cash flow

    • -15.02

      • EBITDA

      • -155.97M

      • Return on Capital %

      • -102.43

      • Return on Equity %

      • -

      • Return on Assets %

      • -102.43

      • Book Value/Share

      • -0.12

      • Shares Outstanding

      • 402.38M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 5.50

        • Credit Rating

        • -

        • Analysts

        • 2

        • EPS Estimate

        • -0.01

        • Cashflow Estimate

        • -0.18

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 82.75

            • Pre-Tax Margin

            • -

            • 39.38

            • Net Profit Margin

            • -

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 0.38

              • 2.92

              • Quick Ratio

              • 0.35

              • 2.35

              • Interest Coverage

              • -10.34

              • 38.02

              • Leverage Ratio

              • -

              • 2.21

              • Book Value/Share

              • -0.12

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -8.33

                • 243.90

                • P/E Ratio 5-Year High

                • -17.28

                • 634.30

                • P/E Ratio 5-Year Low

                • -2.36

                • 124.82

                • Price/Sales Ratio

                • -

                • 9.29

                • Price/Book Value

                • -48.08

                • 8.39

                • Price/Cash Flow Ratio

                • -15.02

                • 49.75

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -102.43

                    (-73.20)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • -

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -169.40M
                  Operating Margin
                  -
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -15.02
                  Ownership

                  Institutional Ownership

                  44.67%

                  Top 10 Institutions

                  38.20%

                  Mutual Fund Ownership

                  12.07%

                  Float

                  60.45%

                  5% / Insider Ownership

                  1.03%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    8,063,306

                  • 0.00

                  • 2.00

                  • iShares Nasdaq Biotechnology

                  •  

                    5,226,435

                  • -0.24

                  • 1.18

                  • Vanguard Small Cap Index

                  •  

                    4,193,462

                  • 3.17

                  • 1.04

                  • Vanguard Total Stock Mkt Idx

                  •  

                    3,906,896

                  • 3.46

                  • 0.97

                  • iShares Russell 2000 (AU)

                  •  

                    3,434,698

                  • -1.81

                  • 0.78

                  • Vanguard Small Cap Growth Index Fund

                  •  

                    2,834,448

                  • 1.21

                  • 0.70

                  • SPDR® S&P Biotech ETF

                  •  

                    2,385,682

                  • -9.85

                  • 0.54

                  • Vanguard Extended Market Index Fund

                  •  

                    2,354,667

                  • 14.08

                  • 0.59

                  • iShares Russell 2000 Growth

                  •  

                    1,603,571

                  • -1.58

                  • 0.36

                  • BlackRock Global Small Cap Fund

                  •  

                    1,323,547

                  • -10.23

                  • 0.33

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Group, Inc.

                  •  

                    14,020,972

                  • +5.67%

                  • 3.57

                  • BlackRock Fund Advisors

                  •  

                    9,624,896

                  • +15.64%

                  • 2.44

                  • Fidelity Management and Research Company

                  •  

                    9,229,268

                  • -7.35%

                  • 2.35

                  • Greywolf Capital Management LP

                  •  

                    6,206,570

                  • +29.88%

                  • 1.58

                  • State Street Corp

                  •  

                    4,846,280

                  • -14.69%

                  • 1.23

                  • BlackRock Advisors LLC

                  •  

                    2,143,055

                  • -10.79%

                  • 0.54

                  • Creative Planning, Inc.

                  •  

                    2,009,230

                  • +0.15%

                  • 0.50

                  • Northern Trust Investments, N.A.

                  •  

                    1,940,756

                  • -5.49%

                  • 0.49

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Growth

                  MannKind Corp a development stage biopharmaceutical company, was incorporated in the state of Delaware on February 14, 1991. The Company is engaged in the discovery, development and commercialization of therapeutic products for disea...moreses such as diabetes. Its product candidate, AFREZZA inhalation powder, is an ultra rapid-acting insulin therapy that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. Its other product MKC253, MKC253 is a Technosphere formulation of GLP-1. Results from a phase 1 trial supported the hypothesis that inhalation of MKC253 may be able to simulate the incretin effect that is lost in patients with type 2 diabetes. Products manufactured in the United States and marketed outside the United States ...moreare subject to certain FDA regulations, as well as regulation by the country in which the products are to be sold.lessless

                  Key People

                  Alfred E. Mann

                  CEO/Chairman of the Board/Director

                  Matthew J. Pfeffer

                  CFO/Chief Accounting Officer/Vice President

                  David Thomson,PhD

                  General Counsel/Secretary/Vice President

                  Diane M. Palumbo

                  Vice President, Divisional

                  Juergen A. Martens,PhD

                  Chief Technology Officer/Vice President, Divisional

                  • MannKind Corp

                  • 28903 North Avenue Paine

                  • Valencia, CA 91355

                  • USA.Map

                  • Phone: +1 661 775-5300

                  • Fax: -

                  • mannkindcorp.com

                  Incorporated

                  1991

                  Employees

                  265

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: